Vaxart Inc. (VXRT) and Its Rivals Contrasting side by side.

As Biotechnology company, Vaxart Inc. (NASDAQ:VXRT) is competing with its competitors based on the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Institutional & Insider Ownership

Vaxart Inc. has 52.2% of its shares owned by institutional investors and an average of 52.39% institutional ownership for its peers. 3.8% of Vaxart Inc. shares are owned by company insiders. Comparatively, 8.89% of all Biotechnology companies shares are owned by company insiders.


On first table we have Vaxart Inc. and its peers’ return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Vaxart Inc. -441.11% -91.00% -40.70%
Industry Average 468.58% 80.16% 25.47%

Earnings and Valuation

The following data compares Vaxart Inc. and its peers’ net profit, top-line revenue and valuation.

Net Income Gross Revenue Price/Earnings Ratio
Vaxart Inc. 18.35M 4.16M 0.00
Industry Average 14.75M 3.15M 89.01

Analyst Ratings

Table 3 provides summary of current ratings for Vaxart Inc. and its peers.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Vaxart Inc. 0 0 0 0.00
Industry Average 1.28 2.04 2.89 2.79

As a group, Biotechnology companies have a potential upside of 137.44%.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Vaxart Inc. and its peers.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Vaxart Inc. -8.74% -18.54% -47.81% -45.6% -68.49% -11.17%
Industry Average 7.88% 20.03% 31.47% 42.06% 73.21% 38.48%

For the past year Vaxart Inc. had bearish trend while Vaxart Inc.’s peers had bullish trend.


Vaxart Inc. has a Current Ratio of 2 and a Quick Ratio of 2. Competitively, Vaxart Inc.’s competitors Current Ratio is 7.48 and has 7.37 Quick Ratio. Vaxart Inc.’s competitors have better ability to pay short and long-term obligations than Vaxart Inc.

Volatility and Risk

Vaxart Inc. is 42.00% less volatile than S&P 500 because the stock has a beta of 0.58. Competitively, Vaxart Inc.’s peers’ beta is 1.91 which is 90.82% more volatile than S&P 500.


Vaxart Inc. does not pay a dividend.


Vaxart Inc.’s competitors show that they’re better in 4 of the 4 indicators compared to the company itself.

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.